Bausch + Lomb Ultra (samfilcon A) Contact Lenses
Bausch and Lomb, Inc., · Decision date Sep 14, 2026
What did the FDA decide?
The FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-14 for P170035/S021, a supplement to the approved application for Bausch + Lomb Ultra (samfilcon A) Contact Lenses. The applicant is Bausch and Lomb, Inc. The supplement reason is listed as a process change affecting a manufacturer, sterilizer, packager or supplier, and the device falls under the soft contact lens, extended wear category in the ophthalmic specialty, product code LPM.
The recorded scope is the expansion and relocation of the monomer mix manufacturing area at the applicant's Rochester, NY facility. This describes a manufacturing-site change within the existing application rather than a new approval of the lens system. The source record includes no supporting documents, so the review basis, any conditions on the decision, and whether the relocated area required separate inspection are not stated here and remain unknown.
FDA approval order statement
expansion and relocation of the monomer mix manufacturing area at Bausch + Lombs manufacturing facility located in Rochester, NY
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 14, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P170035/S021
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch and Lomb, Inc.,
- Product code
- LPM
- Decision code
- OK30
- Decision date
- Sep 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Applicant
- Bausch and Lomb, Inc.,
- Product code
- LPM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P170035. Subsequent supplements may change the device or its indications.
FDA decision timeline
P170035 · Original PMA
Bausch + Lomb Ultra (samfilcon A) Contact Lenses
P170035/S021 received
Application receipt date recorded by FDA.
P170035/S021 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P170035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch and Lomb, Inc., | PMA approval | Apr 30, 2018 | FDA |
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
| Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Sep 2, 2026 | FDA | |
BIOFINITY (COMFILCON A)P080011/S204 | CooperVision, Inc. | PMA supplement | Sep 2, 2026 | FDA |
BIOFINITY (COMFILCON A)P080011 | CooperVision, Inc. | PMA approval | Nov 19, 2008 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch and Lomb, Inc.,
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1400 N. Goodman St., Rochester, NY, 14609
Sources and methodology
- Original FDA record: P170035/S021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


